DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.…
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
DBV Technologies (NASDAQ: DBVT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 179 employees.
The shares were at 9.020 USD on 20 November 2026, down 34.5% over 52 weeks. Its 52-week range is 8.630 USD to 26.18 USD: the price is 65.6% below the high and 4.5% above the low.
Its market capitalisation is 566.82M USD.
DBV Technologies reports return on equity of -87.1% and revenue down 42.9% year over year.
It holds more cash than debt, a net cash position of 158.20M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 March 2027.